Hiteck licenses neurotrophic keratitis eye drop HT006 to Visara
Biotechnology company Hiteck granted Visara exclusive international licensing rights outside Greater China to develop and commercialise investigational Nerve Growth Factor eye drop candidate HT006 2 2
Wuhan-based Hiteck Biological Pharma Co., Ltd. has entered into an exclusive license agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences, for HT006.2.2, a novel eye drop being developed to treat neurotrophic keratitis (NK). Visara will handle worldwide commercialization of the product, excluding Greater China, while Hiteck retains rights within the region.
The innovative eye drop is formulated to improve NGF therapy's practicality for patients, containing enhanced stability and convenience compared to existing treatments. HT006.2.2 demonstrated a favorable safety profile in earlier clinical trials, with some subjects achieving complete corneal healing in a single 8-week course. The agreement aims to advance the program internationally, capitalizing on Visara's ophthalmology expertise and global reach.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
